AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37620807 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide
Number of subjects: 0
Study 37620807 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37620825 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (n=21)
Number of subjects: 38
Study 37620825 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (n=17)
Number of subjects: 38
Study 37620855 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug Resistance Mutation (DRM) testing
Number of subjects: 68
Study 37620855 — intervention group
Group type: EXPERIMENTAL
Intervention: Decentralized DRM testing process
Number of subjects: 68
Study 37620855 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of DRM testing
Number of subjects: 68
Study 37620858 — intervention group
Group type: EXPERIMENTAL
Intervention: C18:1AC exposure
Number of subjects: 0
Study 37620929 — intervention group
Group type: EXPERIMENTAL
Intervention: SMART intervention (twice weekly football, martial arts, and dance coaching)
Number of subjects: 664
Study 37620929 — intervention group
Group type: COMPARATOR
Intervention: Control group (sport as usual)
Number of subjects: 664
Study 37620974 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative glycemic variability (measured by coefficient of variability of blood glucose within 24 hours)
Number of subjects: 177
Study 37621153 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg/day
Number of subjects: 6799
Study 37621153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6799
Study 37621153 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (after withdrawal for ≈30 days)
Number of subjects: 6799
Study 37621153 — intervention group
Group type: COMPARATOR
Intervention: Placebo (after withdrawal for ≈30 days)
Number of subjects: 6799
Study 37621153 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin (change in risk after withdrawal)
Number of subjects: 6799
Study 37621406 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant nivolumab, ipilimumab, and intratumor talimogene laherparepvec (T-VEC)
Number of subjects: 6
Study 37621674 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (10 mg/kg daily for 7 days, followed by 5 mg/kg daily for 7 days)
Number of subjects: 200
Study 37621674 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study 37621674 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin among participants receiving other antibiotics
Number of subjects: 200
Study 37621674 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin among antibiotic-naïve participants
Number of subjects: 200
Study 37621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (ART) without axillary lymph node dissection (ALND)
Number of subjects: 1660
Study 37621686 — intervention group
Group type: COMPARATOR
Intervention: Axillary lymph node dissection (ALND)
Number of subjects: 1660
Study 37621686 — intervention group
Group type: EXPERIMENTAL
Intervention: Axillary radiotherapy (ART)
Number of subjects: 1660
Study 37621688 — intervention group
Group type: EXPERIMENTAL
Intervention: Neratinib plus capecitabine (N+C)
Number of subjects: 0
Study 37621688 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib plus capecitabine (L+C)
Number of subjects: 0
Study 37621919 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated participants
Number of subjects: 2167
Study 37621919 — intervention group
Group type: COMPARATOR
Intervention: Phase 1 (November-December 2020)
Number of subjects: 2167
Study 37621919 — intervention group
Group type: EXPERIMENTAL
Intervention: Phase 2 (November-December 2021)
Number of subjects: 2167
Study 37621919 — intervention group
Group type: EXPERIMENTAL
Intervention: Longitudinal analysis at 6 and 12 months
Number of subjects: 2167
Study 37622035 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (50 mg on day 1, 100 mg twice daily thereafter for 15 days)
Number of subjects: 547
Study 37622035 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 547
Study 37622180 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid and vitamin B12 supplementation
Number of subjects: 102
Study 37622180 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR gene mutations (C677T and A1298C)
Number of subjects: 102
Study 37622180 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T polymorphism
Number of subjects: 102
Study 37622180 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR A1298C polymorphism
Number of subjects: 102
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative management
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative management
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Open surgery
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of surgery
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to re-introduction of normal diet
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: Length of hospital stay
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-day mortality rates
Number of subjects: 316
Study 37622641 — intervention group
Group type: EXPERIMENTAL
Intervention: 90-day mortality rates
Number of subjects: 316
Study 37622649 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported weight
Number of subjects: 4262
Study 37622649 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported length
Number of subjects: 4262
Study 37622649 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-reported BMI
Number of subjects: 4262
Study 37622649 — intervention group
Group type: EXPERIMENTAL
Intervention: Categorisation of BMI z-score
Number of subjects: 4262
Study 37622677 — intervention group
Group type: EXPERIMENTAL
Intervention: Edoxaban
Number of subjects: 2536
Study 37622677 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2536
Study 37622677 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 2536
Study 37622681 — intervention group
Group type: EXPERIMENTAL
Intervention: Semaglutide (2.4 mg)
Number of subjects: 529
Study 37622681 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 529
Study 37622738 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 2.5 mg/kg every 3 weeks
Number of subjects: 223
Study 37622738 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin 3.4 mg/kg every 3 weeks
Number of subjects: 223
Study 37622738 — intervention group
Group type: EXPERIMENTAL
Intervention: Belantamab mafodotin (both doses)
Number of subjects: 223
Study 37622754 — intervention group
Group type: EXPERIMENTAL
Intervention: Measured PPM (moderate: 0.65-0.85 or 0.55-0.70 cm)
Number of subjects: 2463
Study 37622754 — intervention group
Group type: EXPERIMENTAL
Intervention: Predicted PPM
Number of subjects: 2463
Study 37622754 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with PPM
Number of subjects: 2463
Study 37623000 — intervention group
Group type: EXPERIMENTAL
Intervention: Semi-structured interviews with parents regarding perceptions of cancer
Number of subjects: 45
Study 37623007 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of 24 months of ADT, PBRT, and PLNRT
Number of subjects: 46
Study 37623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Waist-to-height ratio
Number of subjects: 220
Study 37623189 — intervention group
Group type: EXPERIMENTAL
Intervention: Finnish Diabetes Risk instrument
Number of subjects: 220
Study 37623203 — intervention group
Group type: EXPERIMENTAL
Intervention: Green coconut water (330 mL)
Number of subjects: 45
Study 37623203 — intervention group
Group type: EXPERIMENTAL
Intervention: Dark chocolate (35 g of 70% dark chocolate)
Number of subjects: 45
Study 37623203 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 45
Study 37623205 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral treatment intervention (IC)
Number of subjects: 0
Study 37623205 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CC)
Number of subjects: 0
Study 37623329 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mmol/kg gadobutrol (half dose)
Number of subjects: 25
Study 37623329 — intervention group
Group type: COMPARATOR
Intervention: 0.1 mmol/kg gadobutrol (single dose)
Number of subjects: 25
Study 37623428 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide
Number of subjects: 519
Study 37623428 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 519
Study 37624364 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable-polymer sirolimus-eluting stents
Number of subjects: 1948
Study 37624364 — intervention group
Group type: COMPARATOR
Intervention: Durable-polymer zotarolimus-eluting stents
Number of subjects: 1948
Study 37624376 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoprotein
Number of subjects: 20
Study 37624389 — intervention group
Group type: EXPERIMENTAL
Intervention: Isometric ballistic and peak torque during maximal voluntary contractions (pkT)
Number of subjects: 70
Study 37624421 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpelisib
Number of subjects: 37
Study 37624488 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrocitinib
Number of subjects: 391
Study 37624488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 391
Study 37624605 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Field Modeling and Analysis (VFMA)
Number of subjects: 189
Study 37624605 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean Sensitivity (MS)
Number of subjects: 189
Study 37624605 — intervention group
Group type: EXPERIMENTAL
Intervention: Hill-of-vision (HOV) derived metric of VTOT
Number of subjects: 189
Study 37624605 — intervention group
Group type: COMPARATOR
Intervention: Open-source implementation (OSI)
Number of subjects: 189
Study 37624619 — intervention group
Group type: EXPERIMENTAL
Intervention: Pirtobrutinib monotherapy (200 mg once daily)
Number of subjects: 120
Study 37624622 — intervention group
Group type: EXPERIMENTAL
Intervention: EPIO intervention (n=132)
Number of subjects: 266
Study 37624622 — intervention group
Group type: COMPARATOR
Intervention: Care-as-usual control group (n=134)
Number of subjects: 266
Study 37624707 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced pattern recognition training using a large-scale interactive image repository (LIIR) through a quiz-based smartphone app.
Number of subjects: 115
Study 37624707 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced pattern recognition training using a LIIR with patient cases delivered by a quiz-based mobile app.
Number of subjects: 115
Study 37624707 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-paced pattern recognition training using a LIIR.
Number of subjects: 115
Study 37624707 — intervention group
Group type: COMPARATOR
Intervention: Control group (no training).
Number of subjects: 115
Study 37624739 — intervention group
Group type: EXPERIMENTAL
Intervention: AAVrh.10hCLN2 administered via intracisternal delivery to cerebrospinal fluid (CSF)
Number of subjects: 0
Study 37624900 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Exposure Treatment (GET Living)
Number of subjects: 68
Study 37624900 — intervention group
Group type: COMPARATOR
Intervention: Multidisciplinary Pain Management (MPM)
Number of subjects: 68
Study 37624901 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus intervention (pain coping skills training and optional support for opioid taper)
Number of subjects: 153
Study 37624901 — intervention group
Group type: COMPARATOR
Intervention: Usual care only
Number of subjects: 153
Study 37625011 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative, nurse-co-ordinated, multi-faceted intervention to lower rehospitalization and death by addressing areas of vulnerability to external challenges to health.
Number of subjects: 203
Study 37625011 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative, nurse-co-ordinated, multi-faceted intervention
Number of subjects: 203
Study 37625034 — intervention group
Group type: EXPERIMENTAL
Intervention: Cannabis use for medical symptoms
Number of subjects: 0
Study 37625034 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37625088 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR1 (E2 80 μg/d with P4 4 mg/d)
Number of subjects: 21
Study 37625088 — intervention group
Group type: EXPERIMENTAL
Intervention: DARE-HRT1 IVR2 (E2 160 μg/d with P4 8 mg/d)
Number of subjects: 21
Study 37625110 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care augmented with a trained community health worker (CHW) for 12 months
Number of subjects: 160
Study 37625110 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 160
Study 37625235 — intervention group
Group type: EXPERIMENTAL
Intervention: Atezolizumab 1200 mg every 3 weeks for 22 cycles with platinum-based chemotherapy and bevacizumab
Number of subjects: 0
Study 37625235 — intervention group
Group type: COMPARATOR
Intervention: Placebo with platinum-based chemotherapy and bevacizumab
Number of subjects: 0
Study 37625235 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab and placebo
Number of subjects: 0
Study 37625386 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-month ambulatory supervised aerobic exercise program (aEP) followed by 6-month home-based aEP with heart rate targeting using ECG
Number of subjects: 132
Study 37625386 — intervention group
Group type: COMPARATOR
Intervention: 2-month ambulatory supervised aerobic exercise program (aEP) followed by 6-month home-based aEP without heart rate targeting
Number of subjects: 132
Study 37625408 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-dysplastic Lugol unstaining lesions (ND-LULs)
Number of subjects: 163
Study 37625434 — intervention group
Group type: EXPERIMENTAL
Intervention: RTS,S/AS01
Number of subjects: 5098
Study 37625434 — intervention group
Group type: COMPARATOR
Intervention: SMC alone
Number of subjects: 5098
Study 37625498 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-radiotherapy LARS prediction model (PORTLARS)
Number of subjects: 868
Study 37625498 — intervention group
Group type: EXPERIMENTAL
Intervention: PORTLARS
Number of subjects: 868
Study 37625518 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg JNJ-10450232 (NTM-006)
Number of subjects: 0
Study 37625518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg JNJ-10450232 (NTM-006)
Number of subjects: 0
Study 37625518 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg acetaminophen
Number of subjects: 0
Study 37625518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37625526 — intervention group
Group type: EXPERIMENTAL
Intervention: Highest quartile of HOMA-IR (indicating higher insulin resistance)
Number of subjects: 2754
Study 37625587 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose esomeprazole (80 mg bolus followed by 12 mg/h for 72 h and a second 80 mg bolus 12 h after the first one)
Number of subjects: 300
Study 37625587 — intervention group
Group type: COMPARATOR
Intervention: Equivolume placebo (sodium chloride 0.9%)
Number of subjects: 300
Study 37625587 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose esomeprazole
Number of subjects: 300
Study 37625684 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Foundations program (9-session perinatal preventative intervention)
Number of subjects: 366
Study 37625684 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 366
Study 37625814 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB2450 (1200 mg every 3 weeks) and anlotinib (10 mg or 12 mg once daily, 2-week on/1-week off)
Number of subjects: 19
Study 37625814 — intervention group
Group type: EXPERIMENTAL
Intervention: TQB2450 and anlotinib
Number of subjects: 19
Study 37626074 — intervention group
Group type: EXPERIMENTAL
Intervention: Active anodal tDCS over the occipital lobe for 28 days
Number of subjects: 0
Study 37626074 — intervention group
Group type: COMPARATOR
Intervention: Sham anodal tDCS over the occipital lobe for 28 days
Number of subjects: 0
Study 37626137 — intervention group
Group type: EXPERIMENTAL
Intervention: Gana V
Number of subjects: 55
Study 37626137 — intervention group
Group type: COMPARATOR
Intervention: Sculptra
Number of subjects: 55
Study 37626170 — intervention group
Group type: EXPERIMENTAL
Intervention: ARO-ANG3
Number of subjects: 61
Study 37626170 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study 37626292 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid
Number of subjects: 315
Study 37626292 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual misoprostol
Number of subjects: 315
Study 37626292 — intervention group
Group type: COMPARATOR
Intervention: Control (oxytocin alone)
Number of subjects: 315
Study 37626303 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex (2 mg/kg)
Number of subjects: 171
Study 37626303 — intervention group
Group type: COMPARATOR
Intervention: Control group (saline infusion)
Number of subjects: 171
Study 37626312 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing modifications (screening windows, doors, ceilings, insecticide-impregnated materials)
Number of subjects: 24
Study 37626312 — intervention group
Group type: EXPERIMENTAL
Intervention: Housing modifications
Number of subjects: 24
Study 37626349 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative attachment anxiety and avoidance
Number of subjects: 263
Study 37626349 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem and health self-efficacy
Number of subjects: 263
Study 37626367 — intervention group
Group type: EXPERIMENTAL
Intervention: Camrelizumab combined with radiotherapy as neoadjuvant therapy
Number of subjects: 25
Study 37626387 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMS-AB (high amylose maize starch - acetylated and butyrylated form)
Number of subjects: 12
Study 37626387 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMS-AB
Number of subjects: 12
Study 37626416 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow mononuclear cells (auto-BM-MNC)
Number of subjects: 24
Study 37626416 — intervention group
Group type: EXPERIMENTAL
Intervention: Allogeneic Wharton jelly-derived mesenchymal stem cells (allo-WJ-MSCs)
Number of subjects: 24
Study 37626416 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 24
Study 37626422 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Behavior Management Implementation Resources (PBMIR)
Number of subjects: 0
Study 37626422 — intervention group
Group type: COMPARATOR
Intervention: No additional implementation support (Control)
Number of subjects: 0
Study 37626422 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMIR
Number of subjects: 0
Study 37626428 — intervention group
Group type: EXPERIMENTAL
Intervention: Technology-assisted peer-delivered Thinking Healthy Programme (THP)
Number of subjects: 980
Study 37626428 — intervention group
Group type: COMPARATOR
Intervention: Standard face-to-face Thinking Healthy Programme delivered by trained health workers
Number of subjects: 980
Study 37626477 — intervention group
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Number of subjects: 45
Study 37628548 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Breathing Method 1 (SB1)
Number of subjects: 79
Study 37628548 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow Breathing Method 2 (SB2)
Number of subjects: 79
Study 37628548 — intervention group
Group type: COMPARATOR
Intervention: Normal Breathing (Control)
Number of subjects: 79
Study 37629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Dizziness Handicap Inventory at one year post-injury
Number of subjects: 64
Study 37629234 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic and injury-related variables, clinical findings, and measures of post-injury symptoms and functioning
Number of subjects: 64
Study 37629318 — intervention group
Group type: EXPERIMENTAL
Intervention: Walk advice (WA) with Nordic pole walking
Number of subjects: 149
Study 37629318 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based structured exercise programs (HSEP)
Number of subjects: 149
Study 37629318 — intervention group
Group type: COMPARATOR
Intervention: Supervised exercise (SEP)
Number of subjects: 149
Study 37629366 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment
Number of subjects: 239
Study 37629366 — intervention group
Group type: COMPARATOR
Intervention: No-CPAP treatment (control)
Number of subjects: 239
Study 37629638 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of a class I pullulan-based medical device, applied two times daily.
Number of subjects: 64
Study 37629638 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract).
Number of subjects: 64
Study 37629671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular Electrical Stimulation
Number of subjects: 0
Study 37629671 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 37631885 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad26.ZEBOV, MVA-BN-Filo Ebola vaccine regimen (two doses with a 56-day interval)
Number of subjects: 0
Study 37632201 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 0.25 mg/dapagliflozin 10 mg QD
Number of subjects: 447
Study 37632201 — intervention group
Group type: EXPERIMENTAL
Intervention: Zibotentan 1.5 mg/dapagliflozin 10 mg QD
Number of subjects: 447
Study 37632201 — intervention group
Group type: COMPARATOR
Intervention: Dapagliflozin 10 mg QD alone
Number of subjects: 447
Study 37632201 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 447
Study 37632240 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine/adrenaline injection
Number of subjects: 1056
Study 37632240 — intervention group
Group type: EXPERIMENTAL
Intervention: Consultation with an allergist
Number of subjects: 1056
Study 37632240 — intervention group
Group type: EXPERIMENTAL
Intervention: Auto-injector prescription
Number of subjects: 1056
Study 37632240 — intervention group
Group type: EXPERIMENTAL
Intervention: Guidelines-based management factors
Number of subjects: 1056
Study 37632249 — intervention group
Group type: EXPERIMENTAL
Intervention: Follicular flushing
Number of subjects: 105